Drug Trial Radar · NCT00163527
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Last checked: Nov 19, 2026Latest source record: Dec 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,054
Actual
Start
Apr 2003
Primary completion
Nov 2005
Study completion Nov 2005
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Sep 14, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma. The aim of the study is to investigate the effect of roflumilast taken orally together with low dose inhaled corticosteroids on lung function. Roflumilast will be administered at one dose level once daily together with inhaled corticosteroids at one dose level twice daily. The study duration consists of a baseline period (2 to 6 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
Conditions
- Asthma
Interventions
RoflumilastDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in forced expiratory volume in 1 second from baseline to final visit.
Locations
24 sites in 24 countries. Site status is shown where the registry gives one.
ALTANA Pharma
Cities in Georgia, Georgia
ALTANA Pharma
Cities in Austria, Austria
ALTANA Pharma
Cities in Croatia, Croatia
ALTANA Pharma
Cities in the Czech Repulik, Czechia
ALTANA Pharma
Cities in Finland, Finland
ALTANA Pharma
Cities in France, France
ALTANA Pharma
Cities in Greece, Greece
ALTANA Pharma
Cities in Hungary, Hungary
ALTANA Pharma
Cities in India, India
ALTANA Pharma
Cities in Ireland, Ireland
ALTANA Pharma
Cities in Italy, Italy
ALTANA Pharma
Cities in New Zealand, New Zealand
ALTANA Pharma
Cities in Norway, Norway
ALTANA Pharma
Cities in Pakistan, Pakistan
ALTANA Pharma
Cities in the Philippines, Philippines
ALTANA Pharma
Cities in Poland, Poland
ALTANA Pharma
Cities in Portugal, Portugal
ALTANA Pharma
Cities in the Russian Federation, Russia
ALTANA Pharma
Sites in Singapore, Singapore
ALTANA Pharma
Cities in South Africa, South Africa
ALTANA Pharma
Cities in Spain, Spain
ALTANA Pharma
Cities in Taiwan, Taiwan
ALTANA Pharma
Cities in Thailand, Thailand
ALTANA Pharma
Cities in the United Kindom, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.